Research and development of an airborne multispectral scanner to measure fire, terrestrial and atmospheric characteristics (50 channel)

The AB184 Spectrometer and the AC12206 High Temperature Blackbody Reference Source Assembly were both successfully developed during this contract effort. The newly developed hardware provide a means of quantifying the spectral characteristics of high temperature fire scenes

Modis-N airborne simulator

All required work associated with the above referenced contract has been successfully completed at this time. The Modis-N Airborne Simulator has been developed from existing AB184 Wildfire spectrometer parts as well as new detector arrays, optical components, and associated mechanical and electrical hardware. The various instrument components have been integrated into an operational system which has undergone extensive laboratory calibration and testing. The instrument has been delivered to NASA Ames where it will be installed on the NASA ER-2. The following paragraphs detail the specific tasks performed during the contract effort, the results obtained during the integration and testing of the instrument, and the conclusions which can be drawn from this effort

Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction, GALACTIC‐HF: baseline characteristics and comparison with contemporary clinical trials

Aims: The safety and efficacy of the novel selective cardiac myosin activator, omecamtiv mecarbil, in patients with heart failure with reduced ejection fraction (HFrEF) is tested in the Global Approach to Lowering Adverse Cardiac outcomes Through Improving Contractility in Heart Failure (GALACTIC‐HF) trial. Here we describe the baseline characteristics of participants in GALACTIC‐HF and how these compare with other contemporary trials. Methods and Results: Adults with established HFrEF, New York Heart Association functional class (NYHA) ≥ II, EF ≤35%, elevated natriuretic peptides and either current hospitalization for HF or history of hospitalization/ emergency department visit for HF within a year were randomized to either placebo or omecamtiv mecarbil (pharmacokinetic‐guided dosing: 25, 37.5 or 50 mg bid). 8256 patients [male (79%), non‐white (22%), mean age 65 years] were enrolled with a mean EF 27%, ischemic etiology in 54%, NYHA II 53% and III/IV 47%, and median NT‐proBNP 1971 pg/mL. HF therapies at baseline were among the most effectively employed in contemporary HF trials. GALACTIC‐HF randomized patients representative of recent HF registries and trials with substantial numbers of patients also having characteristics understudied in previous trials including more from North America (n = 1386), enrolled as inpatients (n = 2084), systolic blood pressure < 100 mmHg (n = 1127), estimated glomerular filtration rate < 30 mL/min/1.73 m2 (n = 528), and treated with sacubitril‐valsartan at baseline (n = 1594). Conclusions: GALACTIC‐HF enrolled a well‐treated, high‐risk population from both inpatient and outpatient settings, which will provide a definitive evaluation of the efficacy and safety of this novel therapy, as well as informing its potential future implementation

Effect of Feeding–Fasting Cycles on Oxygen Consumption and Bioenergetics of Female Yellow Perch

We measured growth and oxygen consumption of age-1 yellow perch Perca flavescens subjected to ad libitum (control) or variable feeding cycles of 2 (i.e., 2 d of feed, 2 d of deprivation), 6, or 12 d for a 72-d period. Individual, female yellow perch (initial weight = 51.9 ± 0.9 g [mean ± SE]) were stocked in 110-L aquaria to provide six replicates per treatment and fed measured rations of live fathead minnow Pimephales promelas. Consumption, absolute growth rate, growth efficiency, and oxygen consumption were similar among feeding regimens. However, growth trajectories for fish on the 2-d cycle were significantly lower than other feed–fast cycles. Hyperphagia occurred in all treatments. Bioenergetics model simulations indicated that consumption was significantly underestimated (t = 5.4, df = 4, P = 0.006), while growth was overestimated (t = −5.5, df = 4, P = 0.005) for fish on the 12-d cycle. However, model errors detected between observed and predicted values were low, ranging from −10.1% to + 7.8%. We found that juvenile yellow perch exhibited compensatory growth (CG), but none of the feed–fast treatments resulted in growth overcompensation. Likewise, we found no evidence that respiration rates varied with CG, implying that yellow perch bioenergetics models could be used to predict the effects of feeding history and CG response on food consumption and fish growth

Cardiac myosin activation with omecamtiv mecarbil in systolic heart failure

BACKGROUND The selective cardiac myosin activator omecamtiv mecarbil has been shown to improve cardiac function in patients with heart failure with a reduced ejection fraction. Its effect on cardiovascular outcomes is unknown. METHODS We randomly assigned 8256 patients (inpatients and outpatients) with symptomatic chronic heart failure and an ejection fraction of 35% or less to receive omecamtiv mecarbil (using pharmacokinetic-guided doses of 25 mg, 37.5 mg, or 50 mg twice daily) or placebo, in addition to standard heart-failure therapy. The primary outcome was a composite of a first heart-failure event (hospitalization or urgent visit for heart failure) or death from cardiovascular causes. RESULTS During a median of 21.8 months, a primary-outcome event occurred in 1523 of 4120 patients (37.0%) in the omecamtiv mecarbil group and in 1607 of 4112 patients (39.1%) in the placebo group (hazard ratio, 0.92; 95% confidence interval [CI], 0.86 to 0.99; P = 0.03). A total of 808 patients (19.6%) and 798 patients (19.4%), respectively, died from cardiovascular causes (hazard ratio, 1.01; 95% CI, 0.92 to 1.11). There was no significant difference between groups in the change from baseline on the Kansas City Cardiomyopathy Questionnaire total symptom score. At week 24, the change from baseline for the median N-terminal pro-B-type natriuretic peptide level was 10% lower in the omecamtiv mecarbil group than in the placebo group; the median cardiac troponin I level was 4 ng per liter higher. The frequency of cardiac ischemic and ventricular arrhythmia events was similar in the two groups. CONCLUSIONS Among patients with heart failure and a reduced ejection, those who received omecamtiv mecarbil had a lower incidence of a composite of a heart-failure event or death from cardiovascular causes than those who received placebo. (Funded by Amgen and others; GALACTIC-HF ClinicalTrials.gov number, NCT02929329; EudraCT number, 2016 -002299-28.)